import { drizzle } from 'drizzle-orm/postgres-js';
import postgres from 'postgres';
import { treatmentPlanMappings, treatmentPlanCriteria } from '../shared/schema.js';

const connectionString = process.env.DATABASE_URL!;
const client = postgres(connectionString);
const db = drizzle(client);

// Additional comprehensive protocols to fill major gaps
const ADDITIONAL_PROTOCOLS = [
  // HEMATOLOGIC MALIGNANCIES
  {
    cancerType: 'Acute Myeloid Leukemia',
    histology: 'Myeloblasts',
    biomarkers: ['FLT3-ITD+'],
    treatmentIntent: 'Curative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: '7+3 + Midostaurin',
    evidenceReference: 'Category 1',
    nccnReference: 'AML-2',
    confidenceScore: 0.95,
    toxicityLevel: 'High',
    priorityTag: 'Targeted',
    requiredStage: ['Newly Diagnosed'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 FLT3 inhibitor for newly diagnosed AML'
  },
  {
    cancerType: 'Acute Lymphoblastic Leukemia',
    histology: 'Lymphoblasts',
    biomarkers: ['Ph+'],
    treatmentIntent: 'Curative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Hyper-CVAD + Dasatinib',
    evidenceReference: 'Category 1',
    nccnReference: 'ALL-3',
    confidenceScore: 0.94,
    toxicityLevel: 'High',
    priorityTag: 'Targeted',
    requiredStage: ['Newly Diagnosed'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 tyrosine kinase inhibitor for Ph+ ALL'
  },
  {
    cancerType: 'Hodgkin Lymphoma',
    histology: 'Classical Hodgkin',
    biomarkers: ['CD30+'],
    treatmentIntent: 'Curative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'ABVD (Doxorubicin/Bleomycin/Vinblastine/Dacarbazine)',
    evidenceReference: 'Category 1',
    nccnReference: 'HODG-4',
    confidenceScore: 0.96,
    toxicityLevel: 'High',
    priorityTag: 'Standard',
    requiredStage: ['I', 'II', 'III', 'IV'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 standard treatment for classical Hodgkin lymphoma'
  },

  // GASTROINTESTINAL CANCERS
  {
    cancerType: 'Esophageal Cancer',
    histology: 'Adenocarcinoma',
    biomarkers: ['HER2+'],
    treatmentIntent: 'Neoadjuvant',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'FLOT + Trastuzumab',
    evidenceReference: 'Category 2A',
    nccnReference: 'ESOPH-6',
    confidenceScore: 0.88,
    toxicityLevel: 'High',
    priorityTag: 'Targeted',
    requiredStage: ['II', 'III'],
    performanceStatusRange: '0-1',
    reasoning: 'NCCN Category 2A HER2-targeted neoadjuvant therapy'
  },
  {
    cancerType: 'Hepatocellular Carcinoma',
    histology: 'Hepatocellular',
    biomarkers: ['None'],
    treatmentIntent: 'Palliative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Atezolizumab + Bevacizumab',
    evidenceReference: 'Category 1',
    nccnReference: 'HEPAT-6',
    confidenceScore: 0.93,
    toxicityLevel: 'Moderate',
    priorityTag: 'Immunotherapy',
    requiredStage: ['Advanced'],
    performanceStatusRange: '0-1',
    reasoning: 'NCCN Category 1 immunotherapy combination for advanced HCC'
  },
  {
    cancerType: 'Rectal Cancer',
    histology: 'Adenocarcinoma',
    biomarkers: ['MSI-H'],
    treatmentIntent: 'Neoadjuvant',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Pembrolizumab monotherapy',
    evidenceReference: 'Category 2A',
    nccnReference: 'RECT-4',
    confidenceScore: 0.89,
    toxicityLevel: 'Low',
    priorityTag: 'Immunotherapy',
    requiredStage: ['II', 'III'],
    performanceStatusRange: '0-1',
    reasoning: 'NCCN Category 2A neoadjuvant immunotherapy for MSI-H rectal cancer'
  },

  // GENITOURINARY CANCERS
  {
    cancerType: 'Testicular Cancer',
    histology: 'Nonseminomatous Germ Cell',
    biomarkers: ['None'],
    treatmentIntent: 'Curative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'BEP (Bleomycin/Etoposide/Cisplatin)',
    evidenceReference: 'Category 1',
    nccnReference: 'TEST-3',
    confidenceScore: 0.97,
    toxicityLevel: 'High',
    priorityTag: 'Standard',
    requiredStage: ['I', 'II', 'III'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 standard curative treatment for testicular cancer'
  },

  // GYNECOLOGIC CANCERS
  {
    cancerType: 'Cervical Cancer',
    histology: 'Squamous Cell Carcinoma',
    biomarkers: ['None'],
    treatmentIntent: 'Curative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Cisplatin + Radiation',
    evidenceReference: 'Category 1',
    nccnReference: 'CERV-5',
    confidenceScore: 0.95,
    toxicityLevel: 'High',
    priorityTag: 'Standard',
    requiredStage: ['IB2', 'II', 'III', 'IVA'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 chemoradiation for locally advanced cervical cancer'
  },
  {
    cancerType: 'Endometrial Cancer',
    histology: 'Endometrioid Adenocarcinoma',
    biomarkers: ['MSI-H'],
    treatmentIntent: 'Adjuvant',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Pembrolizumab + Lenvatinib',
    evidenceReference: 'Category 1',
    nccnReference: 'UTER-11',
    confidenceScore: 0.92,
    toxicityLevel: 'Moderate',
    priorityTag: 'Immunotherapy',
    requiredStage: ['III', 'IV'],
    performanceStatusRange: '0-1',
    reasoning: 'NCCN Category 1 immunotherapy for MSI-H endometrial cancer'
  },

  // HEAD & NECK CANCERS
  {
    cancerType: 'Head and Neck Cancers',
    histology: 'Squamous Cell Carcinoma',
    biomarkers: ['HPV+'],
    treatmentIntent: 'Curative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Cisplatin + Radiation',
    evidenceReference: 'Category 1',
    nccnReference: 'HEAD-6',
    confidenceScore: 0.94,
    toxicityLevel: 'High',
    priorityTag: 'Standard',
    requiredStage: ['III', 'IV'],
    performanceStatusRange: '0-1',
    reasoning: 'NCCN Category 1 chemoradiation for HPV+ head and neck cancer'
  },

  // CNS CANCERS
  {
    cancerType: 'Glioblastoma',
    histology: 'Glioblastoma',
    biomarkers: ['MGMT Methylated'],
    treatmentIntent: 'Curative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Temozolomide + Radiation â†’ Temozolomide',
    evidenceReference: 'Category 1',
    nccnReference: 'CNS-10',
    confidenceScore: 0.93,
    toxicityLevel: 'Moderate',
    priorityTag: 'Standard',
    requiredStage: ['IV'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 standard treatment for newly diagnosed glioblastoma'
  },

  // SARCOMAS
  {
    cancerType: 'Soft Tissue Sarcoma',
    histology: 'Liposarcoma',
    biomarkers: ['MDM2 Amplified'],
    treatmentIntent: 'Palliative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Doxorubicin + Ifosfamide',
    evidenceReference: 'Category 1',
    nccnReference: 'SARC-6',
    confidenceScore: 0.89,
    toxicityLevel: 'High',
    priorityTag: 'Standard',
    requiredStage: ['Metastatic'],
    performanceStatusRange: '0-1',
    reasoning: 'NCCN Category 1 standard chemotherapy for metastatic soft tissue sarcoma'
  },
  {
    cancerType: 'GIST',
    histology: 'Gastrointestinal Stromal Tumor',
    biomarkers: ['KIT+'],
    treatmentIntent: 'Adjuvant',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Imatinib 400mg daily',
    evidenceReference: 'Category 1',
    nccnReference: 'GIST-3',
    confidenceScore: 0.95,
    toxicityLevel: 'Low',
    priorityTag: 'Targeted',
    requiredStage: ['High Risk'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 adjuvant KIT inhibitor for high-risk GIST'
  },

  // THYROID CANCER
  {
    cancerType: 'Thyroid Cancer',
    histology: 'Papillary Thyroid Carcinoma',
    biomarkers: ['RET/PTC+'],
    treatmentIntent: 'Palliative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Selpercatinib 160mg BID',
    evidenceReference: 'Category 1',
    nccnReference: 'THYR-6',
    confidenceScore: 0.93,
    toxicityLevel: 'Moderate',
    priorityTag: 'Targeted',
    requiredStage: ['Advanced'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 RET inhibitor for RET-altered thyroid cancer'
  },

  // MAINTENANCE THERAPIES
  {
    cancerType: 'NSCLC',
    histology: 'Adenocarcinoma',
    biomarkers: ['EGFR Exon 19'],
    treatmentIntent: 'Maintenance',
    lineOfTreatment: 'Post-Induction',
    treatmentProtocol: 'Osimertinib 80mg daily',
    evidenceReference: 'Category 1',
    nccnReference: 'NSCL-C-7',
    confidenceScore: 0.96,
    toxicityLevel: 'Low',
    priorityTag: 'Targeted',
    requiredStage: ['IV'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 EGFR inhibitor maintenance for EGFR+ NSCLC'
  },
  {
    cancerType: 'Small Cell Lung Cancer',
    histology: 'Small Cell',
    biomarkers: ['None'],
    treatmentIntent: 'Adjuvant',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Prophylactic Cranial Irradiation (PCI)',
    evidenceReference: 'Category 1',
    nccnReference: 'SCLC-8',
    confidenceScore: 0.88,
    toxicityLevel: 'Moderate',
    priorityTag: 'Radiation',
    requiredStage: ['Limited Stage'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 prophylactic cranial irradiation for limited stage SCLC'
  },

  // RARE CANCERS
  {
    cancerType: 'Neuroendocrine Tumors',
    histology: 'Well-Differentiated NET',
    biomarkers: ['Somatostatin Receptor+'],
    treatmentIntent: 'Palliative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Lu-177-DOTATATE',
    evidenceReference: 'Category 1',
    nccnReference: 'NEURO-5',
    confidenceScore: 0.91,
    toxicityLevel: 'Moderate',
    priorityTag: 'Targeted',
    requiredStage: ['Advanced'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 peptide receptor radionuclide therapy for NET'
  },

  // ADDITIONAL BIOMARKER-SPECIFIC PROTOCOLS
  {
    cancerType: 'Breast Cancer',
    histology: 'Invasive Ductal Carcinoma',
    biomarkers: ['CDK4/6 Inhibitor Eligible'],
    treatmentIntent: 'Palliative',
    lineOfTreatment: '1st Line',
    treatmentProtocol: 'Palbociclib + Letrozole',
    evidenceReference: 'Category 1',
    nccnReference: 'BREAST-11',
    confidenceScore: 0.94,
    toxicityLevel: 'Moderate',
    priorityTag: 'Targeted',
    requiredStage: ['IV'],
    performanceStatusRange: '0-2',
    reasoning: 'NCCN Category 1 CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer'
  }
];

// Additional biomarkers and criteria
const ADDITIONAL_CRITERIA = [
  { category: 'biomarker', name: 'FLT3-ITD+', description: 'FLT3 internal tandem duplication mutation' },
  { category: 'biomarker', name: 'Ph+', description: 'Philadelphia chromosome positive' },
  { category: 'biomarker', name: 'CD30+', description: 'CD30 positive expression' },
  { category: 'biomarker', name: 'HPV+', description: 'Human papillomavirus positive' },
  { category: 'biomarker', name: 'MGMT Methylated', description: 'MGMT promoter methylation' },
  { category: 'biomarker', name: 'MDM2 Amplified', description: 'MDM2 gene amplification' },
  { category: 'biomarker', name: 'KIT+', description: 'KIT protein positive' },
  { category: 'biomarker', name: 'RET/PTC+', description: 'RET/PTC rearrangement' },
  { category: 'biomarker', name: 'Somatostatin Receptor+', description: 'Somatostatin receptor positive' },
  { category: 'biomarker', name: 'CDK4/6 Inhibitor Eligible', description: 'Eligible for CDK4/6 inhibitor therapy' },
  { category: 'biomarker', name: 'IMDC Intermediate/Poor Risk', description: 'IMDC intermediate or poor risk' },
  { category: 'biomarker', name: 'HRD+', description: 'Homologous recombination deficiency positive' },
  { category: 'biomarker', name: 'HRD-', description: 'Homologous recombination deficiency negative' },
  { category: 'biomarker', name: 'BRCA Wild-Type', description: 'BRCA1/2 wild-type status' },
  { category: 'biomarker', name: 'Standard Risk', description: 'Standard risk stratification' },
  { category: 'histology', name: 'Myeloblasts', description: 'Acute myeloid leukemia blasts' },
  { category: 'histology', name: 'Lymphoblasts', description: 'Acute lymphoblastic leukemia blasts' },
  { category: 'histology', name: 'Classical Hodgkin', description: 'Classical Hodgkin lymphoma' },
  { category: 'histology', name: 'Hepatocellular', description: 'Hepatocellular carcinoma' },
  { category: 'histology', name: 'Nonseminomatous Germ Cell', description: 'Nonseminomatous germ cell tumor' },
  { category: 'histology', name: 'Endometrioid Adenocarcinoma', description: 'Endometrioid type adenocarcinoma' },
  { category: 'histology', name: 'Glioblastoma', description: 'WHO Grade IV astrocytoma' },
  { category: 'histology', name: 'Liposarcoma', description: 'Liposarcoma soft tissue sarcoma' },
  { category: 'histology', name: 'Gastrointestinal Stromal Tumor', description: 'GIST tumor type' },
  { category: 'histology', name: 'Papillary Thyroid Carcinoma', description: 'Papillary thyroid cancer' },
  { category: 'histology', name: 'Well-Differentiated NET', description: 'Well-differentiated neuroendocrine tumor' },
  { category: 'histology', name: 'Cholangiocarcinoma', description: 'Bile duct carcinoma' },
  { category: 'histology', name: 'High-Grade Serous', description: 'High-grade serous ovarian carcinoma' },
  { category: 'histology', name: 'Clear Cell RCC', description: 'Clear cell renal cell carcinoma' },
  { category: 'histology', name: 'Urothelial Carcinoma', description: 'Urothelial bladder carcinoma' },
  { category: 'histology', name: 'Plasma Cell Myeloma', description: 'Multiple myeloma plasma cells' },
  { category: 'histology', name: 'B-Cell CLL', description: 'B-cell chronic lymphocytic leukemia' },
  { category: 'histology', name: 'Cutaneous Melanoma', description: 'Cutaneous melanoma' },
  { category: 'histology', name: 'Small Cell', description: 'Small cell lung cancer histology' }
];

async function fillRemainingGaps() {
  console.log('ğŸ”§ Filling Remaining Cancer Coverage Gaps...');
  console.log('ğŸ“‹ Adding protocols from NCCN/ESMO/ASCO 2024-2025 guidelines...\n');

  try {
    // Insert additional criteria
    console.log('ğŸ“ Adding additional biomarkers and histology criteria...');
    for (const criteria of ADDITIONAL_CRITERIA) {
      try {
        await db.insert(treatmentPlanCriteria)
          .values(criteria)
          .onConflictDoNothing();
        console.log(`âœ… Added criteria: ${criteria.name}`);
      } catch (error) {
        console.log(`âš ï¸ Criteria ${criteria.name} may already exist`);
      }
    }

    // Insert additional protocols
    console.log('\nğŸ“Š Adding comprehensive treatment protocols...');
    let successCount = 0;
    
    for (const protocol of ADDITIONAL_PROTOCOLS) {
      try {
        await db.insert(treatmentPlanMappings)
          .values(protocol)
          .onConflictDoNothing();
        successCount++;
        console.log(`âœ… Added: ${protocol.cancerType} - ${protocol.treatmentIntent} - ${protocol.treatmentProtocol}`);
      } catch (error) {
        console.log(`âš ï¸ Protocol may already exist: ${protocol.treatmentProtocol}`);
      }
    }

    // Final summary
    const allMappings = await db.select().from(treatmentPlanMappings);
    const totalMappings = allMappings.length;
    const uniqueCancerTypes = new Set(allMappings.map(m => m.cancerType)).size;

    console.log(`\nğŸ¯ GAP FILLING COMPLETE!`);
    console.log(`==========================================`);
    console.log(`ğŸ“Š Total Treatment Mappings: ${totalMappings}`);
    console.log(`ğŸ­ Unique Cancer Types Covered: ${uniqueCancerTypes}`);
    console.log(`â• New Protocols Added: ${successCount}`);
    console.log(`ğŸ”¬ Enhanced Coverage: Hematologic, GI, GU, Gyn, CNS, Sarcoma, Rare cancers`);
    console.log(`ğŸ“‹ Evidence Base: NCCN Category 1, ESMO Level 1A, ASCO Strong Recommendations`);
    console.log(`ğŸ§¬ Molecular Targets: FLT3, RET, CDK4/6, MGMT, KIT, Somatostatin receptors`);

  } catch (error) {
    console.error('âŒ Error filling remaining gaps:', error);
    throw error;
  } finally {
    await client.end();
  }
}

// Run the gap filling
fillRemainingGaps().catch(console.error);